Literature DB >> 20622140

Novel approach to early detection of doxorubicin cardiotoxicity by gadolinium-enhanced cardiovascular magnetic resonance imaging in an experimental model.

James C Lightfoot1, Ralph B D'Agostino, Craig A Hamilton, Jennifer Jordan, Frank M Torti, Nancy D Kock, James Jordan, Susan Workman, W Gregory Hundley.   

Abstract

BACKGROUND: We sought to determine whether cardiovascular magnetic resonance measures of gadolinium (Gd) signal intensity (SI) within the left ventricular myocardium are associated with future changes in left ventricular ejection fraction (LVEF) after receipt of doxorubicin (DOX). METHODS AND
RESULTS: Forty Sprague-Dawley rats were divided into 3 groups scheduled to receive weekly intravenous doses of normal saline (n = 7), 1.5 mg/kg DOX (n = 19), or 2.5 mg/kg DOX (n = 14). Magnetic resonance determinations of LVEF and myocardial Gd-SI were performed before and at 2, 4, 7, and 10 weeks after DOX initiation. During treatment, animals were euthanized at different time points so that histopathologic assessments of the left ventricular myocardium could be obtained. Within-group analyses were performed to examine time-dependent relations between Gd-SI and primary events (deterioration in LVEF or an unanticipated death). Six of 19 animals receiving 1.5 mg/kg DOX and 10 of 14 animals receiving 2.5 mg/kg DOX experienced a primary event; no normal saline animals experienced a primary event. In animals with a primary event, histopathologic evidence of myocellular vacuolization occurred (P = 0.04), and the Gd-SI was elevated relative to baseline at the time of the event (P < 0.0001) and during the measurement period before the event (P = 0.0001). In all animals (including normal saline) without an event, measures of Gd-SI did not differ from baseline.
CONCLUSIONS: After DOX, low serial measures of Gd-SI predict an absence of an LVEF drop or unanticipated death. An increase in Gd-SI after DOX forecasts a subsequent drop in LVEF as well as histopathologic evidence of intracellular vacuolization consistent with DOX cardiotoxicity.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20622140      PMCID: PMC3068484          DOI: 10.1161/CIRCIMAGING.109.918540

Source DB:  PubMed          Journal:  Circ Cardiovasc Imaging        ISSN: 1941-9651            Impact factor:   7.792


  18 in total

1.  Protective effect of lycopene on adriamycin-induced cardiotoxicity and nephrotoxicity.

Authors:  Seval Yilmaz; Ahmet Atessahin; Engin Sahna; Izzet Karahan; Songul Ozer
Journal:  Toxicology       Date:  2005-12-01       Impact factor: 4.221

2.  Subclinical cardiotoxic effects of anthracyclines as assessed by magnetic resonance imaging-a pilot study.

Authors:  R Wassmuth; S Lentzsch; U Erdbruegger; J Schulz-Menger; B Doerken; R Dietz; M G Friedrich
Journal:  Am Heart J       Date:  2001-06       Impact factor: 4.749

3.  Relation between Gd-DTPA contrast enhancement and regional inotropic response in the periphery and center of myocardial infarction.

Authors:  B L Gerber; C E Rochitte; D A Bluemke; J A Melin; P Crosille; L C Becker; J A Lima
Journal:  Circulation       Date:  2001-08-28       Impact factor: 29.690

4.  Importance of imaging method over imaging modality in noninvasive determination of left ventricular volumes and ejection fraction: assessment by two- and three-dimensional echocardiography and magnetic resonance imaging.

Authors:  M L Chuang; M G Hibberd; C J Salton; R A Beaudin; M F Riley; R A Parker; P S Douglas; W J Manning
Journal:  J Am Coll Cardiol       Date:  2000-02       Impact factor: 24.094

5.  Transmural extent of acute myocardial infarction predicts long-term improvement in contractile function.

Authors:  K M Choi; R J Kim; G Gubernikoff; J D Vargas; M Parker; R M Judd
Journal:  Circulation       Date:  2001-09-04       Impact factor: 29.690

Review 6.  Overview of cardiac pathology in relation to anthracycline cardiotoxicity.

Authors:  V J Ferrans
Journal:  Cancer Treat Rep       Date:  1978-06

7.  Adriamycin cardiotoxicity and proton nuclear magnetic resonance relaxation properties.

Authors:  R C Thompson; R C Canby; E W Lojeski; A V Ratner; J T Fallon; G M Pohost
Journal:  Am Heart J       Date:  1987-06       Impact factor: 4.749

8.  T1 mapping in patients with acute myocardial infarction.

Authors:  Daniel R Messroghli; Thoralf Niendorf; Jeanette Schulz-Menger; Rainer Dietz; Matthias G Friedrich
Journal:  J Cardiovasc Magn Reson       Date:  2003       Impact factor: 5.364

9.  Doxorubicin cardiotoxicity: assessment of late left ventricular dysfunction by radionuclide cineangiography.

Authors:  J S Gottdiener; D J Mathisen; J S Borer; R O Bonow; C E Myers; L H Barr; D E Schwartz; S L Bacharach; M V Green; S A Rosenberg
Journal:  Ann Intern Med       Date:  1981-04       Impact factor: 25.391

10.  Electrolyte and morphologic alterations of myocardium in adriamycin-treated rabbits.

Authors:  H M Olson; D M Young; D J Prieur; A F LeRoy; R L Reagan
Journal:  Am J Pathol       Date:  1974-12       Impact factor: 4.307

View more
  33 in total

1.  Improving prediction of cardiovascular complications of cancer therapy: what does the future hold?

Authors:  Ana Barac
Journal:  Future Cardiol       Date:  2015-08-04

Review 2.  Cardiotoxicity due to chemotherapy: role of cardiac imaging.

Authors:  Frédéric Poulin; Paaladinesh Thavendiranathan
Journal:  Curr Cardiol Rep       Date:  2015-03       Impact factor: 2.931

3.  Imaging for cardiotoxicity in cancer patients.

Authors:  Jose Banchs; John L Jefferies; Juan Carlos Plana; W Gregory Hundley
Journal:  Tex Heart Inst J       Date:  2011

4.  Characterization of the Changes in Cardiac Structure and Function in Mice Treated With Anthracyclines Using Serial Cardiac Magnetic Resonance Imaging.

Authors:  Hoshang Farhad; Pedro V Staziaki; Daniel Addison; Otavio R Coelho-Filho; Ravi V Shah; Richard N Mitchell; Balint Szilveszter; Siddique A Abbasi; Raymond Y Kwong; Marielle Scherrer-Crosbie; Udo Hoffmann; Michael Jerosch-Herold; Tomas G Neilan
Journal:  Circ Cardiovasc Imaging       Date:  2016-12       Impact factor: 7.792

Review 5.  Running on empty: cardiovascular reserve capacity and late effects of therapy in cancer survivorship.

Authors:  Graeme J Koelwyn; Michel Khouri; John R Mackey; Pamela S Douglas; Lee W Jones
Journal:  J Clin Oncol       Date:  2012-10-08       Impact factor: 44.544

Review 6.  Noninvasive imaging of cardiovascular injury related to the treatment of cancer.

Authors:  Suwat Kongbundansuk; W Gregory Hundley
Journal:  JACC Cardiovasc Imaging       Date:  2014-08

7.  Frequency of Left Ventricular End-Diastolic Volume-Mediated Declines in Ejection Fraction in Patients Receiving Potentially Cardiotoxic Cancer Treatment.

Authors:  Giselle C Meléndez; Bunyapon Sukpraphrute; Ralph B D'Agostino; Jennifer H Jordan; Heidi D Klepin; Leslie Ellis; Zanetta Lamar; Sujethra Vasu; Glenn Lesser; Gregory L Burke; Kathryn E Weaver; William O Ntim; W Gregory Hundley
Journal:  Am J Cardiol       Date:  2017-03-22       Impact factor: 2.778

Review 8.  The Role of Cardiac MRI in Animal Models of Cardiotoxicity: Hopes and Challenges.

Authors:  Carolyn J Park; Mary E Branch; Sujethra Vasu; Giselle C Meléndez
Journal:  J Cardiovasc Transl Res       Date:  2020-04-04       Impact factor: 4.132

Review 9.  Cancer therapy-induced cardiac toxicity in early breast cancer: addressing the unresolved issues.

Authors:  Michel G Khouri; Pamela S Douglas; John R Mackey; Miguel Martin; Jessica M Scott; Marielle Scherrer-Crosbie; Lee W Jones
Journal:  Circulation       Date:  2012-12-04       Impact factor: 29.690

10.  Left ventricular mass in patients with a cardiomyopathy after treatment with anthracyclines.

Authors:  Tomas G Neilan; Otavio R Coelho-Filho; Diego Pena-Herrera; Ravi V Shah; Michael Jerosch-Herold; Sanjeev A Francis; Javid Moslehi; Raymond Y Kwong
Journal:  Am J Cardiol       Date:  2012-08-21       Impact factor: 2.778

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.